HARBIN, China, Feb. 27, 2012 /PRNewswire-Asia-FirstCall/ --
Weikang Bio-Technology Group Co., Inc.
(WKBT.PK)("Weikang" or the "Company"), a leading developer,
manufacturer and marketer of Traditional Chinese Medicine (TCM),
Western prescription and OTC pharmaceuticals and other health and
nutritional products in the People's
Republic of China, today announced that the Company is
expected to report its fiscal 2011 net profit of between
$26 million to $28 million with EPS
between $0.78 and $0.84 and revenue
between $100 million and $102
millions.
"We are excited and confident about our results for 2011 and
growth prospects beyond. The economy in China as we feel in general is slowing down,
however we believe that the market for our high-quality
therapeutics and health enhancement will continue to expand as
China is expected to become the
second largest pharmaceutical market by 2020," commented Mr.
Yin Wang, Chairman and CEO of
Weikang. "Moreover, our pipeline products on which our research
team is focused address a large number of health problems and have
a broad consumer appeal."
About Weikang Bio-Technology Group Co., Inc.
Weikang Bio-Technology Group Co., Inc. is principally engaged in
developing, manufacturing and distributing Traditional Chinese
Medicine (TCM), and health and nutritional supplements in
China, in compliance with
requisite Chinese licenses and approvals. The Company is also
expanding its business scope to develop, manufacture and distribute
Chinese herbal extract products and GMP certified western
prescription and OTC pharmaceuticals through its acquisition of
Tianfang Pharmaceutical Co., Ltd. For more information,
please visit http://www.weikangbio.com.
Contact:
Yue Kang (Venus)
+86 451-8835-5530
+86 15846588061
Email: weikangbio@yahoo.com
Safe Harbor Statement
Certain statements in this press release constitute
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. These forward-looking statements are often identified
by the use of forward-looking terminology such as "believes,"
"expects" or similar expressions, involve known and unknown risks
and uncertainties. Although the Company believes that the
expectations reflected in these forward-looking statements are
reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. You should not
place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. The Company's
actual results could differ materially from those anticipated in
these forward-looking statements as a result of a variety of
factors, including those discussed in the Company's periodic
reports that are filed with the Securities and Exchange Commission
and available on its website (http://www.sec.gov).
All forward-looking statements attributable to the Company or
persons acting on its behalf are expressly qualified in their
entirety by these factors. Other than as required under the
securities laws, the Company does not assume a duty to update these
forward-looking statements.
SOURCE Weikang Bio-Technology Group Co., Inc.